Author - Michael

Formulation Lab

New international patent application

  • New injectable drug delivery formulation technology
  • Co-invented by Formulytica and SERI researchers under collaborative research agreement
  • Potential ‘platform technology’ with broad therapeutic potential

Formulytica (Melbourne, Australia) and Singapore Eye Research Institute (SERI; Singapore) are pleased to announce that an international (PCT) patent application was filed in Singapore in May 2021. An outcome of their collaborative research, the patent covers a new drug delivery technology with application for reduction of scarring following eye surgery. This comes after formulation development and in vitro and in vivo proof of concept studies successfully demonstrated the applicability of this formulation technology, which has potentially broad applicability across a range of other therapeutic areas. Further work is ongoing to refine the technology and proceed to pre-clinical safety studies and eventually Phase 1 clinical studies.

About Formulytica Pty Ltd

Formulytica is an Australian innovative technology developer and service provider specialising in topical and injectable formulation development. Formulytica’s services include new product development and it specializes in the analytical science of semi-solid formulations for topical application utilised in dermatology, pharmaceutical, cosmetic, veterinary and personal care products, such as skincare and haircare. Formulytica’s injectable parenteral expertise covers solution and lipid-based formulations, in biologics, as well as small organic molecules. For more information, please visit

About SERI

Established in 1997, the Singapore Eye Research Institute (SERI) is Singapore’s national research institute for ophthalmic and vision research. It is the research arm of the Singapore National Eye Centre, and affiliated to the National University of Singapore and the Duke-NUS Medical School. In two decades, SERI has grown from a team of 5 to over 250 staff, encompassing clinician scientists, scientists, fellows, students, support staff, as well as more than 245 distinguished adjunct faculty members to become the largest eye research institute in the Asia-Pacific region.  As of Mar 2021, SERI has published 4,353 peer-reviewed papers supported by S$346 million in competitive research grants.  SERI has trained more than 210 current and past graduate students; and has been conferred over 714 national & international awards and 145 patents. SERI further undertakes eye research in collaboration with local & international medical centres and research institutions, which has ensured a high level of research competency & skills transfer. Notably, SERI’s research has translated to actual patient success stories & significant improvements in eye care delivery. Today, SERI is recognized as a pioneering center for high quality eye research in Asia, with breakthrough discoveries that has translated to significant paradigm shift in eye care delivery. For more information, please visit



Our summer interns 2019-2020


Formulytica has hosted 3 Monash University students for their industry internship. These students are from various backgrounds such as marketing, biomedical science and media communications.

As part of Formulytica’s mission and values, we encourage innovative collaborations to produce exemplary results. Although working on separate projects, our interns have been moving forward as a cohesive unit, all the while gaining experience and expanding their knowledge in their fields. We wish them the very best with their future studies and careers.


Formulytica participates in the Third Precision Medicine & Medical Care and Aging International Forum in Tianjin, China, December 7-8


Our CEO, Dr Richard Buchta, joined with other international delegates at the Third Precision Medicine & Medical Care and Aging International Forum in Tianjin, China this week. The event, hosted by Beroni Group, had the theme of “Innovation Driving Development, Technology Leading Future”. Scientists, experts and scholars in the healthcare industry from China, America, Japan, Australia presented their latest scientific and technological achievements towards innovative therapies for cancer and aging.


Austrade delegation at Taiwan Healthcare Expo, December 5-8


Formulytica joined with the Australian Biomedical & Digital Health Showcase hosted by Austrade Taipei as part of the 2019 Taiwan Healthcare+ Expo. The event aims to promote Australian capabilities and build commercial biomedical partnerships between Australia and Taiwan and the region. Our CEO, Dr Richard Buchta, participated in site tours and B2B meetings, and met with a number of prospective new clients in the biotechnology and pharmaceutical industry to discuss their topical and injectable drug formulation needs.


Richard Buchta to speak at Biotech Development Lab “Formula for Success”, September 13


Formulation is key to the success of any pharmaceutical product. Formulytica’s CEO Dr Richard Buchta will speak about what is required for successful formulation development, technical transfer and scale up, including a number of case studies. Richard is presenting along with a range of other experts at the upcoming 2019 Biotech Development Lab, “Formula for Success”, hosted by BioMelbourne Network at the Victorian Comprehensive Cancer Centre, 13 September. For more information, visit this link


Formulytica offers liposomal formulation development services


As part of Formulytica’s expanding offerings in injectable and topical formulation development services, we are pleased to announce that we have the capability to assist our clients in developing liposomal formulations.

Liposomes are small, spherical particles composed of one or more phospholipid bilayers. Due to their small size (typically ranging from 100 to 200 nm in diameter), liposomes are often referred to as nanomedicine or nanotechnology. The size and structure of liposomes can be controlled by their formulation composition, and their method of manufacture. Some of the advantages of liposomes as a drug delivery vehicle are their ability to improve the solubility and stability of poorly water soluble drugs, their ability to increase the therapeutic window and bioavailability of drugs, and their excellent safety profile and biocompatibility.

Please contact us for more information about our liposomal formulation development services.


Formulytica attends BIO Asia-Taiwan Conference and Exhibition, July 24-28


Formulytica is attending the 2019 BIO Asia-Taiwan International Conference and Exhibition in Taipei, July 24-28 as part of the Austrade delegation.

Be sure to visit the Australian pavilion to chat with our CEO, Dr Richard Buchta, and learn more about how Formulytica can partner with you to develop your topical or injectable formulations.

More about BIO Asia Taiwan:

For the past 16 years, BioTaiwan has established itself as one of the largest annual biotech events in Asia. Expanding on this legacy, the Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan Bio) have come together to present BIO Asia-Taiwan, taking place July 24-28 in Taipei.  Themed “Biotech as the Next Growth Engine for Asia”, this year’s event will attract more than 1,500 attendees from 25 countries representing biomedical, pharmaceutical, genomics, biotech services, equipment and instruments, academic research, cosmetology products and bio-based healthcare.


Formulytica attends BIO International Convention in Philadelphia, June 3-6


Formulytica will be joining the Victorian Government and Ausbiotech trade delegation at the 2019 BIO International Convention in Philadelphia, June 3-6.

Be sure to schedule a meeting with us through BIO One-on-One Partnering.

More about BIO:

BIO International Convention in Philadelphia, June 3-6, celebrates the globally important innovations in biotech that start with one: one meeting, one theory, one trial, one breakthrough. This is the only event where you can access the global biotech community via BIO One-on-One Partnering, attend 150+ education sessions and network with 16,000+ attendees from 67 countries. Discover the next generation of cutting-edge products, therapies, and cures all week long. Learn more at


Rheology of semi solid topical formulations – new insights and applications


Robert Houlden Formulation Director at Formulytica will give a number of talks this year. The talks will be based on Formulytica’s work utilising rheology to understand formulation physical properties of semi solid dosage forms, including cream, gel, ointment, thickened solutions and foam. Particular applications in comparison to the reference listed drug form, predicting physical stability and understanding spreadability and effect on aesthetics of these topical formulations.

During February and March 2018, Robert will speak at ASCC (Australian Society of Cosmetic Chemists) members in Sydney, Adelaide Brisbane and Perth. In July 2018 Robert will be a speaker at the International Skin Care Conference in Thailand to talk on rheology and topical formulations. Details of the conference in Thailand can be found here